Eagle Pharmaceuticals (EGRX) Receives Final FDA Approval for PEMFEXY

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Eagle Pharmaceuticals (EGRX) Receives Final FDA Approval for PEMFEXY

Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY™ (Pemetrexed for Injection)

February 10, 2020 9:54 AM EST

-- Eagle has exclusive rights to commercialize product for four months beginning February 1, 2022 --

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its novel product, PEMFEXY (pemetrexed for injection), a branded alternative to ALIMTA®.

We are pleased to receive final approval from FDA and look forward to making PEMFEXY available to the patients who can benefit. Our initial market exclusivity for PEMFEXY represents a significant... More